A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

Disease Sites:

Neuro-Oncology

Staging:

Phase II

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Cabozantinib, XL184

Principal Investigator(s):

Mohler, Alexander

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

05-30-2025

Trial Type:

Treatment

Protocol ID:

VICC-ITNEU23261

National Clinical Trial ID:

NCT05425004

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available